Figure 4.

Suppressive effects on CD4⁺ T cells after stimulation with ConA, PHA, and SEB. The percentages of proliferating CD3⁺TCR-γδ⁻CD4⁺ T cells for human (upper row) and GMs (bottom row) are presented after 5 days of in-vitro cultivation in combination with four different immunomodulating compounds. S indicates the percentage of the stimulated controls without compound treatment. The compounds are presented by their abbreviations: abatacept (A), belatacept (B), rapamycin (R), and tofacitinib (T). Data are based on six different donors for each species. The height of the bar and black dots correspond to back-transformed estimated marginal means, and whiskers represent the upper and lower 95% confidence intervals of the estimated marginal means. Raw data are shown as (+). P-value brackets display contrasts significant at 10% FDR: *p ≤ 0.1, **p ≤ 0.05, ***p ≤ 0.01, ****p ≤ 0.001.